Alnylam Pharmaceuticals Inc

ALNY: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|m@LOCK|CP#$$LOCK|^ZNnZ>

Alnylam Earnings: Amvuttra Uptake Drives Sales; Durability of Demand in Focus Amid Competition

Alnylam posted first‑quarter net product revenue above $1 billion, driven by $890 million in Amvuttra sales across ATTR‑CM and ATTR‑PN. Management reaffirmed 2026 guidance of $5.1 billion at the midpoint in total net product revenue, implying 71% growth versus 2025.

Sponsor Center